{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:25:22Z","timestamp":1760059522211,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lodz","award":["503\/1-090-02\/503-11-001"],"award-info":[{"award-number":["503\/1-090-02\/503-11-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Osteogenesis imperfecta (OI) is a rare bone dysplasia that occurs with a frequency of 1\/15,000\u201320,000 live births. It is characterized by increased susceptibility of bone fractures, skeletal deformities, low stature, and low bone mass. It results in impaired production of type I collagen. About 90% of people with OI have heterozygous mutations in the COL1A1 and COL1A2 genes. Fibroblast growth factor 23 (FGF23) is a protein involved in the regulation of phosphate and 1,25-dihydroxyvitamin D3 metabolism on a negative feedback basis. FGF23 is secreted by osteocytes in response to increased serum calcitriol and phosphorus. The purpose of this study was to evaluate the concentration of FGF23 among children with osteogenesis imperfecta and the differences in reference values in a healthy population of children and adolescents. Then, this study sought to evaluate how the course of osteogenesis imperfecta, including type of disease, number of bone fractures, and bone mineral density, are related to FGF23 concentration. The study included 47 children aged 3 to 17 years with a diagnosis of osteogenesis imperfecta, confirmed by genetic tests. The patients were hospitalized at the Department from August 2019 to September 2020 and were treated with intravenous infusions of sodium pamidronate. The course of the disease was analyzed, including the number of bone fractures, clinical symptoms, and anthropometric parameters, and bone densitometry was performed by dual X-ray absorptiometry (DXA) in Total Body Less Head (TBLH) and Spine options with Z-score evaluation. FGF23 concentration was determined by the ELISA method. The study was prospective in nature. Results: The mean level of FGF23 in the study group of patients was 645.09 pg\/mL and was within the reference values for the developmental age population. There was no significant correlation between FGF23 concentration and anthropometric measurements: body weight (p = 0.267), height (p = 0.429), gender (p = 0.291), or pubertal stage (p = 0.223) in the study group of patients. FGF23 levels were not related to the number of fractures (p = 0.749), the number of sodium pamidronate cycles administered (p = 0.580), bone mineral density parameters (Z-score), the form of osteogenesis imperfecta (p = 0.156), or the genetic test result (p = 0.573). FGF23 levels decrease with age (r = \u22120.32, p = 0.030) and BMI (r = \u22120.34, p = 0.020). The level of FGF23 in patients with osteogenesis imperfecta is lower among older children and those having a higher BMI. This index cannot be a diagnostic tool in this group of patients, for no differences were found between the concentrations in patients with osteogenesis imperfecta and the developmental age population.<\/jats:p>","DOI":"10.3390\/ijms26136007","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T09:08:44Z","timestamp":1750669724000},"page":"6007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Somatic Development and Course of Osteogenesis Imperfecta on FGF23 Levels in Children"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0610-9897","authenticated-orcid":false,"given":"Agnieszka","family":"Byrwa-Sztaba","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Neonatal Pathology and Metabolic Bone Diseases of Medical University of Lodz, 91-738 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Jakubowska-Pietkiewicz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Neonatal Pathology and Metabolic Bone Diseases of Medical University of Lodz, 91-738 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Deguchi, M., Tsuji, S., Katsura, D., Kasahara, K., Kimura, F., and Murakami, T. (2021). Current Overview of Osteogenesis Imperfecta. Medicina, 57.","DOI":"10.3390\/medicina57050464"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.12998\/wjcc.v11.i12.2604","article-title":"Classification of osteogenesis imperfecta: Importance for prophylaxis and genetic counseling","volume":"11","author":"Panzaru","year":"2023","journal-title":"World J. Clin. Cases"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jped.2014.05.003","article-title":"What is new in genetics and osteogenesis imperfecta classification?","volume":"90","author":"Valadares","year":"2014","journal-title":"J. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104926","DOI":"10.1016\/j.ejmg.2024.104926","article-title":"Imaging in osteogenesis imperfecta: Where we are and where we are going","volume":"68","author":"Gazzotti","year":"2024","journal-title":"Eur. J. Med. Genet."},{"key":"ref_5","first-page":"397","article-title":"Osteogenesis imperfecta","volume":"10","author":"Rauch","year":"2013","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/MOP.0000000000000813","article-title":"Osteogenesis imperfecta: Advancements in genetics and treatment","volume":"31","author":"Rossi","year":"2019","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-20-0299","article-title":"Osteogenesis imperfecta: An update on clinical features and therapies","volume":"183","author":"Marom","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","article-title":"Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate therapy","volume":"18","author":"Rauch","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e10558","DOI":"10.1002\/jbm4.10558","article-title":"FGF23 and Vitamin D Metabolism","volume":"5","author":"Latic","year":"2021","journal-title":"JBMR Plus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4248\/BR201302002","article-title":"FGF23 and Phosphate Wasting Disorders","volume":"1","author":"Huang","year":"2013","journal-title":"Bone Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/164_2019_330","article-title":"FGF23 and Bone and Mineral Metabolism","volume":"262","author":"Fukumoto","year":"2020","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Michigami, T. (2022). Roles of osteocytes in phosphate metabolism. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.967774"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/JME-20-0178","article-title":"FGF23 signalling and physiology","volume":"66","author":"Ho","year":"2021","journal-title":"J. Mol. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pons-Belda, O.D., Alonso-\u00c1lvarez, M.A., Gonz\u00e1lez-Rodr\u00edguez, J.D., Mantec\u00f3n-Fern\u00e1ndez, L., and Santos-Rodr\u00edguez, F. (2023). Mineral Metabolism in Children: Interrelation between Vitamin D and FGF23. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076661"},{"key":"ref_18","first-page":"119","article-title":"Siatki centylowe dla oceny wzrastania i stanu od\u017cywienia polskich dzieci i m\u0142odzie\u017cy od urodzenia do 18 roku \u017cycia Percentile charts for growth and nutritional status assessment in Polish children and adolescents from birth to 18 year of age","volume":"12","author":"Grajda","year":"2025","journal-title":"Stand. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1542\/peds.111.5.1030","article-title":"Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV","volume":"111","author":"Zeitlin","year":"2003","journal-title":"Pediatrics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1302\/1863-2548.13.180185","article-title":"Complex spine deformities in young patients with severe osteogenesis imperfecta: Current concepts review","volume":"13","author":"Castelein","year":"2019","journal-title":"J. Child. Orthop."},{"key":"ref_21","first-page":"77","article-title":"Modern approach to children with osteogenesis imperfecta","volume":"12","author":"Zeitlin","year":"2003","journal-title":"J. Pediatr. Orthop. B"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41390-023-02550-0","article-title":"Standardized growth charts for children with osteogenesis imperfecta","volume":"94","author":"Robinson","year":"2023","journal-title":"Pediatr. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00431-016-2839-y","article-title":"Developmental charts for children with osteogenesis imperfecta, type I (body height, body weight and BMI)","volume":"176","author":"Graff","year":"2017","journal-title":"Eur. J. Pediatr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/adc.80.6.524","article-title":"Anthropometry of patients with osteogenesis imperfecta","volume":"80","author":"Lund","year":"1999","journal-title":"Arch. Dis. Child."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment","volume":"164","author":"Sillence","year":"2014","journal-title":"Am. J. Med Genet. Part A"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MOP.0b013e3282f35f03","article-title":"Surgical treatment of osteogenesis imperfecta: Current concepts","volume":"20","author":"Esposito","year":"2008","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry","volume":"16","author":"Schousboe","year":"2013","journal-title":"J. Clin. Densitom."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jakubowska-Pietkiewicz, E., Ma\u0107kowska, A., Nowicki, J., and Wo\u017aniak, E. (2022). Anthropometrics of Polish children with osteogenesis imperfecta: A single-centre retrospective cohort study. BMC Pediatr., 22.","DOI":"10.1186\/s12887-022-03621-7"},{"key":"ref_29","first-page":"489","article-title":"Cross-sectional and longitudinal growth patterns in osteogenesis imperfecta: Implications for clinical care","volume":"79","author":"Brennen","year":"2015","journal-title":"Pediatr. Res."},{"key":"ref_30","unstructured":"(2023, February 21). Oty\u0142o\u015b\u0107 u Dzieci\u2014Same z Niej Nie Wyrosn\u0105|Pacjent, Available online: https:\/\/pacjent.gov.pl\/aktualnosc\/otylosc-u-dzieci-same-z-niej-nie-wyrosna."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4103\/ijem.IJEM_220_17","article-title":"Osteogenesis Imperfecta","volume":"21","author":"Sam","year":"2017","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e10174","DOI":"10.1002\/jbm4.10174","article-title":"Osteogenesis Imperfecta: New Perspectives From Clinical and Translational Research","volume":"3","author":"Tauer","year":"2019","journal-title":"JBMR Plus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15528","DOI":"10.1021\/bi981147u","article-title":"Nuclear magnetic resonance shows asymmetric loss of triple helix in peptides modeling a collagen mutation in brittle bone disease","volume":"37","author":"Liu","year":"1998","journal-title":"Biochemistry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1515\/med-2021-0288","article-title":"Serum intact fibroblast growth factor 23 in healthy paediatric population","volume":"16","author":"Stanczyk","year":"2021","journal-title":"Open Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jpeds.2014.06.027","article-title":"Fibroblast Growth Factor-23 in Obese, Normotensive Adolescents is Associated with Adverse Cardiac Structure","volume":"165","author":"Ali","year":"2014","journal-title":"J. Pediatr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40618-023-02202-4","article-title":"Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets","volume":"47","author":"Baroncelli","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00774-011-0262-z","article-title":"Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta","volume":"29","author":"Kitaoka","year":"2011","journal-title":"J. Bone Miner. Metab."},{"key":"ref_38","unstructured":"Emmanuel, M., and Bokor, B.R. (2022). Tanner Stages. The SAGE Encyclopedia of Lifespan Human Development, StatPearls."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","article-title":"User\u2019s guide to correlation coefficients","volume":"18","author":"Akoglu","year":"2018","journal-title":"Turk. J. Emerg. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:56:56Z","timestamp":1760032616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":39,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136007"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136007","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,6,23]]}}}